Cargando…

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

BACKGROUND: Immune checkpoint inhibitors and chemotherapy can synergistically increase efficacy in a variety of malignancies. We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hui, Qin, Shukui, Liu, Ying, Chen, Zhendong, Ren, Zhenggang, Xiong, Jianping, Meng, Zhiqiang, Zhang, Xiao, Wang, Linna, Zhang, Xiaojing, Zou, Jianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106453/ https://www.ncbi.nlm.nih.gov/pubmed/33976538 http://dx.doi.org/10.2147/DDDT.S304857

Ejemplares similares

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
por: Mei, Kuimin, et al.
Publicado: (2021)

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
por: Wang, Feng, et al.
Publicado: (2020)

Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4
por: Qin, Shukui, et al.
Publicado: (2017)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
por: Qin, Shukui, et al.
Publicado: (2018)

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
por: Schultheis, B., et al.
Publicado: (2013)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study
por: Qi, Fei, et al.
Publicado: (2018)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2022)

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study
por: Lin, Chia‐Chi, et al.
Publicado: (2020)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
por: Ren, Yanqiao, et al.
Publicado: (2022)

Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report
por: Chen, Zhihong, et al.
Publicado: (2023)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
por: Li, Jian-Xu, et al.
Publicado: (2022)

Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China
por: Zhang, Dan, et al.
Publicado: (2019)

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020)

FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer
por: CHEN, WENJUN, et al.
Publicado: (2014)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

The Predictive Role of Inflammatory Biomarkers for Treatment Response and Progression-Free Survival in Patients with Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy with FOLFOX Regimen: A Preliminary Study
por: Zhao, Yang, et al.
Publicado: (2023)

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study
por: Li, Shao-Hua, et al.
Publicado: (2023)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020)

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019)

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
por: Qin, Shukui, et al.
Publicado: (2018)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis
por: Zhang, Hailing, et al.
Publicado: (2021)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study
por: Zhou, Haiyu, et al.
Publicado: (2021)

A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma
por: Ravindran, Nishal, et al.
Publicado: (2020)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients
por: Zhou, Juan, et al.
Publicado: (2016)

Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
por: Liu, Mengyao, et al.
Publicado: (2018)

Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ihmneoptodqgtio3ntg4eap8k5